Address for Correspondence: Uzm. Dr. Havva Yeşil Çınkır Ankara Onkoloji Hastanesi, Tıbbi Onkoloji Bölümü Ankara - Türkiye e-mail: doctoryesil82@yahoo.com Available at www.actaoncologicaturcica.com
İntraperitoneal tedavi; over neoplazmları; peritoneovajinal fistül
chemotherapy showed 16-month OS advantage for optimally resected stage III EOC (1). However, catheter-related complications are common reasons (13-40%) for discontinuation of IP treatment. These are abdominal pain, bleeding, blockage, leakage, movement, malfunction, and/or access problems (2). Peritoneovaginal fistula is a rare complication of IP treatment, “leaky vaginal cuff” was the reason for discontinuation of treatment 2 of the 71 patients in a study (3). Although the significant improvement on survival, IP chemotherapy should be given carefully
Intraperitoneal treatment; ovarian neoplasms; peritoneovaginal fistula
Birincil Dil | Türkçe |
---|---|
Bölüm | Makaleler |
Yazarlar | |
Yayımlanma Tarihi | 21 Ağustos 2014 |
Yayımlandığı Sayı | Yıl 2014 Cilt: 47 Sayı: 1 |